NAV

Sodium bisulfite

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Sodium bisulfite is an ingredient in parenteral nutrition products for patients with severe liver disorders.

Generic Name
Sodium bisulfite
DrugBank Accession Number
DB14015
Background

Sodium bisulfite has been used externally for parasitic skin diseases and as a gastrointestinal antiseptic.

Type
Small Molecule
Groups
Approved
Structure
Similar Structures
Weight
Average: 104.061
Monoisotopic: 103.954409263
Chemical Formula
HNaO3S
Synonyms
  • Bisulfite de sodium
  • Natriumbisulfit
  • Natriumhydrogensulfit
  • primäres Natriumsulfit
  • saures Natriumsulfit
  • Sodium bisulfite
  • sodium bisulphite
  • sodium hydrogen sulfite
  • sodium hydrogensulfite
External IDs
  • E222
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to manageHepatic encephalopathy (he)•••••••••••••••••••••
Used in combination to manageHepatic encephalopathy (he)•••••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
CisplatinThe therapeutic efficacy of Cisplatin can be decreased when used in combination with Sodium bisulfite.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
HEPATAMINE %8 500 ML(SETLI)Sodium bisulfite (0.01 %) + Ademetionine (0.24 %) + Adenine (0.8 %) + Ascorbic acid (0.6 %) + Aspartame (0.9 %) + Biotin (0.1 %) + Calcifediol (0.9 %) + Cysteine (0.066 %) + Lysine (0.61 %) + Methionine (0.5 %) + NADH (0.45 %) + Phosphoric acid (0.115 %) + Thiamine (0.02 %) + Tryptophan (1.1 %) + Tyrosine (0.1 %) + Valine (0.77 %) + Vitamin A (0.84 %)SolutionIntravenousECZACIBAŞI-BAXTER HASTANE ÜRÜNLERİ SAN.VE TİC. A.Ş.1990-01-162024-01-23Turkey flag
HEPATAMINE %8 500 ML(SETSIZ)Sodium bisulfite (0.01 %) + Ademetionine (0.24 %) + Adenine (0.8 %) + Ascorbic acid (0.6 %) + Aspartame (0.9 %) + Biotin (0.1 %) + Calcifediol (0.9 %) + Cysteine (0.066 %) + Lysine (0.61 %) + Methionine (0.5 %) + NADH (0.45 %) + Phosphoric acid (0.115 %) + Thiamine (0.02 %) + Tryptophan (1.1 %) + Tyrosine (0.1 %) + Valine (0.77 %) + Vitamin A (0.84 %)SolutionIntravenousECZACIBAŞI-BAXTER HASTANE ÜRÜNLERİ SAN.VE TİC. A.Ş.1990-01-162024-01-23Turkey flag
LIBAVIT-K 20 MG AMPUL, 5 ADETSodium bisulfite (6 mg/2ml) + Menadione (20 mg/2ml) + Sodium chloride (12.6 mg/2ml)Injection, solutionLİBA LABORATUARLARI A.Ş.1980-09-22Not applicableTurkey flag
NEOFLEKS IZOPLEN-P % 5 DEKSTROZLU DENGELI ELEKTROLIT IÇEREN INFÜZYON IÇIN ÇÖZELTI 1000 ML SETLISodium bisulfite (0.021 g/100ml) + D-glucose (5.5 g/100ml) + Dipotassium phosphate (0.026 g/100ml) + Sodium lactate (0.26 g/100ml) + Magnesium chloride hexahydrate (0.031 g/100ml) + Potassium chloride (0.13 g/100ml)SolutionIntravenousTURKTIPSAN SAĞLIK TURİZM EĞİTİM VE TİC. A.Ş.2011-05-26Not applicableTurkey flag
NEOFLEKS IZOPLEN-P % 5 DEKSTROZLU DENGELI ELEKTROLIT IÇEREN INFÜZYON IÇIN ÇÖZELTI 1000 ML SETSIZSodium bisulfite (0.021 g/100ml) + D-glucose (5.5 g/100ml) + Dipotassium phosphate (0.026 g/100ml) + Sodium lactate (0.26 g/100ml) + Magnesium chloride hexahydrate (0.031 g/100ml) + Potassium chloride (0.13 g/100ml)SolutionIntravenousTURKTIPSAN SAĞLIK TURİZM EĞİTİM VE TİC. A.Ş.2011-05-26Not applicableTurkey flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
TZX5469Z6I
CAS number
7631-90-5
InChI Key
DWAQJAXMDSEUJJ-UHFFFAOYSA-M
InChI
InChI=1S/Na.H2O3S/c;1-4(2)3/h;(H2,1,2,3)/q+1;/p-1
IUPAC Name
sodium hydrogen sulfite
SMILES
[Na+].OS([O-])=O

References

General References
  1. TITCK Product Information: Hepatamine (Admetionine, Adenine, Ascorbic Acid, Aspartame, Biotin, Calcifediol, Cysteine, Lysine, Methionine, NADH, Phosphoric Acid, Sodium Bisulfite. Thiamine, Tryptophan, Tyrosine, Valine, Vitamin A) Intravenous Solution [Link]
ChemSpider
571016
RxNav
1366858
ChEBI
26709
ChEMBL
CHEMBL1689285
Wikipedia
Sodium_bisulfite

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solution
SolutionIntravenous
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-1.2Chemaxon
pKa (Strongest Acidic)1.7Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area60.36 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity11.21 m3·mol-1Chemaxon
Polarizability5.43 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-114.43012
predicted
DeepCCS 1.0 (2019)
[M+H]+116.25029
predicted
DeepCCS 1.0 (2019)
[M+Na]+124.61406
predicted
DeepCCS 1.0 (2019)

Drug created at April 25, 2018 22:30 / Updated at May 14, 2021 01:06